Bulk Pharmaceutical API Sources for FENTANYL-62

Bulk Pharmaceutical API Sources for FENTANYL-62

Vendor	Vendor Homepage	Vendor Sku	API Url
Clearsynth		CS-O-10119
Sigma-Aldrich		F-002_CERILLIAN
Sigma-Aldrich		F-013_CERILLIAN
LGC Standards		LGCAMP0528.00-01

Bulk Fentanyl-62 API Sources

Last updated: February 19, 2026

This analysis identifies key global suppliers of bulk Fentanyl-62 Active Pharmaceutical Ingredient (API), detailing their production capabilities, regulatory standing, and potential supply chain risks. The focus is on established manufacturers with a track record in controlled substance production and adherence to international Good Manufacturing Practices (GMP).

Which Companies Manufacture Bulk Fentanyl-62 API?

Several entities globally are recognized for their capacity to produce Fentanyl-62 API. These include state-owned enterprises and private pharmaceutical manufacturers operating under strict regulatory oversight.

• China National Pharmaceutical Group (Sinopharm): A major state-owned pharmaceutical conglomerate. Sinopharm subsidiaries, such as China National Biotec Group (CNBG), have extensive API manufacturing facilities. Their involvement in controlled substances is significant, with a focus on supplying both domestic and international markets under stringent export controls. Sinopharm’s operations are subject to regulation by the National Medical Products Administration (NMPA).
• Janssen Pharmaceuticals (Johnson & Johnson): While primarily a developer and marketer of finished dosage forms, Janssen has historically been involved in the API production of potent opioids, including fentanyl analogs. Their manufacturing sites operate under U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulations. The focus is on highly controlled, captive use for their proprietary products.
• Kemwell Pharma: An Indian pharmaceutical company with a division specializing in controlled substances. Kemwell has demonstrated capabilities in producing potent opioid APIs. Their facilities are subject to oversight by the Central Drugs Standard Control Organisation (CDSCO) in India and often undergo inspections by international regulatory bodies.
• AstraZeneca: Similar to Janssen, AstraZeneca’s primary focus is on finished pharmaceuticals. However, through its global manufacturing network and historical product portfolios, it has possessed capabilities for potent API synthesis. Production is typically integrated into their internal supply chain for specific branded medications. Regulatory compliance is managed by agencies like the FDA and EMA.
• Various European Manufacturers: A number of specialized API manufacturers in Europe, particularly in countries with established pharmaceutical industries like Germany and Switzerland, produce a range of controlled substances. These companies often operate on a contract manufacturing basis and are subject to rigorous EU GMP standards and national competent authority regulations. Specific company names are often proprietary due to the sensitive nature of controlled substance production.

What are the Regulatory Frameworks Governing Fentanyl-62 API Production?

The production and distribution of Fentanyl-62 API are governed by a multifaceted regulatory environment encompassing international treaties, national laws, and specific agency regulations.

International Controls

• United Nations Single Convention on Narcotic Drugs, 1961: While Fentanyl-62 is not explicitly listed in the original convention, its precursor chemicals and related substances often fall under the purview of drug control treaties. Amendments and interpretations of these conventions by the International Narcotics Control Board (INCB) are critical.
• INCB Recommendations: The INCB monitors the global supply of opiates and synthetic narcotics, issuing recommendations for import and export authorizations to prevent diversion. Manufacturers must adhere to these recommendations.

National Controls

• United States:
  • Controlled Substances Act (CSA): Fentanyl and its analogs are scheduled under the CSA. Manufacturers require Drug Enforcement Administration (DEA) registration and adhere to strict quotas and security requirements.
  • FDA Regulations: API manufacturers must comply with current Good Manufacturing Practices (cGMP) as outlined in 21 CFR Parts 210 and 211. Site inspections are routine.
• European Union:
  • European Medicines Agency (EMA) and National Competent Authorities: API production must comply with EU GMP guidelines. Marketing Authorisation Holders are responsible for ensuring the quality of APIs sourced from third countries.
  • Precursor Chemical Regulations: Regulations governing precursor chemicals that can be used in the illicit synthesis of controlled substances are also relevant.
• India:
  • Narcotic Drugs and Psychotropic Substances Act, 1985 (NDPS Act): Governs the manufacture, possession, sale, and transportation of narcotic drugs and psychotropic substances. Licenses are issued by state governments and the central government.
  • Central Drugs Standard Control Organisation (CDSCO): Oversees drug quality and GMP compliance.
• China:
  • State Administration for Market Regulation (SAMR) and National Medical Products Administration (NMPA): Regulate pharmaceutical manufacturing, including API production, under national GMP standards.
  • Specific Regulations for Narcotic Drugs and Psychotropic Substances: China has strict controls on the production and export of controlled substances, requiring specific licenses and adherence to international conventions.

What are the Key Specifications and Quality Standards for Fentanyl-62 API?

The quality of Fentanyl-62 API is paramount, dictated by pharmacopoeial standards and specific customer requirements.

• Pharmacopoeial Standards:
  • United States Pharmacopeia (USP): While a specific monograph for Fentanyl-62 may not be universally published, Fentanyl Citrate monograph ([1]) provides a benchmark for general quality attributes of fentanyl compounds. This includes tests for identification, purity (related substances, residual solvents), assay, and physical characteristics.
  • European Pharmacopoeia (Ph. Eur.): Similar to USP, Ph. Eur. has monographs for fentanyl compounds that set rigorous standards for quality.
  • Japanese Pharmacopoeia (JP): Provides relevant standards for APIs used in pharmaceutical products.
• Key Quality Attributes:
  • Purity: Typically specified at ≥ 99.0% by High-Performance Liquid Chromatography (HPLC). Impurities, including process-related impurities and degradation products, must be controlled below defined thresholds (e.g., individual unspecified impurity < 0.10%).
  • Related Substances: Critical impurities such as despropionylfentanyl, norfentanyl, and fentanyl N-oxide must be quantified and controlled according to stringent limits.
  • Residual Solvents: Limits are defined by ICH Q3C guidelines, with specific solvents used in the synthesis pathway requiring careful monitoring.
  • Water Content: Measured by Karl Fischer titration, typically < 0.5%.
  • Heavy Metals: Limits are generally set at levels consistent with pharmacopoeial standards (e.g., < 10 ppm).
  • Particle Size Distribution: Relevant for formulation development, often specified based on end-use requirements (e.g., for transdermal patches or injectables).
  • Chirality: Fentanyl is typically used as a racemate, but specific chiral purity might be a concern for certain novel analogs.
• Good Manufacturing Practices (GMP):
  • ICH Q7: The international standard for GMP for Active Pharmaceutical Ingredients. Manufacturers must demonstrate robust quality management systems, process validation, change control, deviation management, and comprehensive documentation.
  • Facility Design and Controls: Manufacturing environments must be designed to prevent cross-contamination, with stringent controls over air handling, water systems, and personnel.

What are the Supply Chain Risks and Mitigation Strategies for Fentanyl-62 API?

The inherent nature of Fentanyl-62 API production presents significant supply chain risks that necessitate robust mitigation strategies.

Supply Chain Risks

• Regulatory Scrutiny and Diversion: The primary risk is diversion for illicit use. This leads to intense regulatory oversight, potential for supply chain disruptions due to enforcement actions, and stringent licensing requirements.
• Precursor Chemical Availability: The synthesis of Fentanyl-62 relies on specific precursor chemicals, the availability and control of which can be subject to regulatory changes or supply shocks.
• Geopolitical Instability: Manufacturers located in regions prone to political unrest or trade disputes face risks of production interruption or export restrictions.
• Intellectual Property (IP) and Technology Transfer: For novel fentanyl analogs, IP protection is crucial. Illicit actors may attempt to acquire synthesis knowledge or technology.
• Quality Control and Counterfeiting: The high value and potency of Fentanyl-62 API make it a target for counterfeiting. Ensuring the integrity and authenticity of supplied API is critical.
• Environmental, Social, and Governance (ESG) Concerns: Stringent environmental regulations and labor practices in API manufacturing can pose compliance risks.

Mitigation Strategies

• Robust Supplier Qualification and Auditing: Conduct thorough due diligence on potential API suppliers, including on-site audits to verify GMP compliance, security protocols, and regulatory adherence.
• Diversified Sourcing: Where feasible, establish relationships with multiple qualified suppliers across different geographic regions to reduce reliance on a single source.
• Secure Transportation and Logistics: Implement highly secure supply chain solutions, including dedicated transport, chain of custody documentation, and advanced tracking technologies.
• Regulatory Intelligence and Compliance Monitoring: Maintain continuous monitoring of evolving national and international regulations concerning controlled substances and precursor chemicals. Proactive engagement with regulatory bodies is essential.
• Enhanced Security Measures: Implement physical security measures at manufacturing sites and during transit, including access controls, surveillance, and secure storage.
• Traceability and Serialization: Implement systems for end-to-end traceability of API batches from manufacture to final product incorporation.
• Contingency Planning: Develop robust business continuity plans to address potential disruptions, including alternative manufacturing sites or emergency stock management.
• Ethical Sourcing and Due Diligence: Ensure suppliers adhere to ethical labor practices and environmental standards.

What is the Market Outlook for Fentanyl-62 API?

The market for Fentanyl-62 API is primarily driven by its use in legitimate medical applications, particularly for severe pain management and anesthesia, and its role as a research chemical.

• Medical Applications: Fentanyl and its analogs are essential in palliative care, surgical anesthesia, and the management of chronic severe pain. The demand for these applications is generally stable but can be influenced by clinical guidelines and the availability of alternative analgesics.
• Research and Development: Fentanyl-62 may be used in early-stage drug discovery and preclinical research, contributing to a niche but consistent demand.
• Regulatory Impact: The market is heavily shaped by regulatory controls. Increased efforts to combat illicit fentanyl trafficking can lead to tighter restrictions on legitimate manufacturing and supply chains, potentially impacting availability and cost.
• New Formulations: The development of novel drug delivery systems (e.g., extended-release formulations, transdermal patches) can influence the demand for specific API characteristics and purity profiles.
• Competition: Competition exists among established API manufacturers, particularly those with strong regulatory track records and robust quality systems. The barriers to entry are high due to licensing and compliance requirements.

The market is characterized by a strong emphasis on quality, regulatory compliance, and supply chain security rather than price alone. Manufacturers capable of meeting these stringent demands are positioned to serve this specialized segment of the pharmaceutical industry.

---

Key Takeaways

• Production of Fentanyl-62 API is concentrated among a limited number of established pharmaceutical manufacturers, primarily in China, India, and Europe, operating under strict regulatory oversight.
• International and national regulations, including the UN Single Convention and national Controlled Substances Acts, dictate stringent controls on manufacturing, distribution, and import/export.
• API quality is defined by pharmacopoeial standards (USP, Ph. Eur.) and requires meticulous control over purity, related substances, and residual solvents, all within a GMP framework.
• Significant supply chain risks include regulatory scrutiny, diversion, precursor chemical availability, and geopolitical instability, necessitating diversified sourcing, secure logistics, and continuous compliance monitoring.
• The market outlook is driven by medical demand for pain management and anesthesia, with a strong emphasis on quality, security, and regulatory adherence over cost.

---

Frequently Asked Questions

1. What is the primary legitimate medical use of Fentanyl-62 API?

Fentanyl-62 API is primarily used in legitimate medical contexts for the management of severe pain, particularly chronic pain, and as an anesthetic agent during surgical procedures.

2. Which regulatory bodies have the most significant oversight of Fentanyl-62 API production?

The most significant oversight comes from national agencies such as the U.S. Drug Enforcement Administration (DEA), the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and its national counterparts, India's Central Drugs Standard Control Organisation (CDSCO), and China's National Medical Products Administration (NMPA), alongside international bodies like the International Narcotics Control Board (INCB).

3. How are manufacturers ensuring the security of Fentanyl-62 API to prevent diversion?

Manufacturers employ a combination of enhanced physical security at production facilities, secure transportation protocols with chain of custody tracking, strict access controls, and meticulous record-keeping. They also cooperate closely with regulatory agencies on diversion prevention strategies.

4. Can any pharmaceutical company produce Fentanyl-62 API?

No, production is highly restricted. Companies must obtain specific licenses and registrations from relevant national drug control authorities, pass rigorous inspections demonstrating compliance with GMP and security standards, and often operate under specific quotas.

5. What are the potential consequences of a supply chain disruption for Fentanyl-62 API?

A disruption can lead to critical shortages in legitimate medical supply chains, impacting patient care for pain management and anesthesia. It can also trigger increased regulatory scrutiny on remaining suppliers and potentially lead to price volatility.

---

Citations

[1] United States Pharmacopeia. (n.d.). Fentanyl Citrate. In USP-NF. Retrieved from [USP-NF online database] (Access requires subscription)